Prediction of the pharmacokinetics and adverse events of nab-paclitaxel in patients with pancreatic cancer by magnetic resonance imaging

Prediction of the pharmacokinetics and adverse events of nab-paclitaxel in patients with pancreatic cancer by magnetic resonance imaging - Prediction of the pharmacokinetics and adverse events of nab-paclitaxel by MRI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026180

Enrollment

Registered

2017-02-22

Start date

2017-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Performance Status 0-1(ECOG) 2.No peripheral neuropathy at baseline 3.Total Bilirubin<=1.2 mg/dL 4.Aspartate aminotransferase<=100 U/L 5.Alanine aminotransferase<=100 U/L

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to Gd-EOB-DTPA

Design outcomes

Primary

Measure	Time frame
The relationship between the pretreatment parenchymal hepatic enhancement effect of Gd-EOB-DTPA MRI and the plasma paclitaxel concentration.	—

Secondary

Measure	Time frame
The relationship among enhancement effect of Gd-EOB-DTPA, development of peripheral neuropathy during chemotherapy, and gene polymorphisms of hepatic transporter	—

Countries

Japan

Contacts

Public ContactHironao Okubo

Juntendo University Nerima Hospital Department of Gastroenterlogy

drokubo@juntendo-nerima.jp+81-3-5923-3111

Outcome results